Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0018801 (heart failure)
 72,216 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Dobutamine (DOB) showed a dose dependent positive introphic effect on the right ventricular muscle of vagotomized Beagle dogs under pentobarbital anesthesia. Positve inotropic effects of other catecholamines (CA) decreased in the following order; isoproterenol (Iso, 115) greater than norepinephrine (NE, 15) greater than DOB (1) greater than dopamine (DA, 0.36). Brachiocephalic arterial flow was also increased by DOB with a positive inotropic effect in the right ventricular muscle. Though the positive inotropic effect of DOB was slightly decreased by pretreatment with phenoxybenzamine, such was almost completely antagonized by propranolol. Contractions of isolated cat papillary muscle driven by electrical stimulation (12 beats/min) were increased by CA in the following order; Iso (17) greater than NE (3) greater than epinephrine (2.5) greater than DOB (1) greater than DA (1 greater than). Activity of DOB to induce spontaneous contractions of papillary muscle was weakest among these CA. To determine the arrhythmogenic effect of these CA, coronary ligated Beagle dogs were employed, in which the anterior descending branch of the left coronary artery was ligated. Arrhythmogenic activity of DOB was weaker than other CA employed both in early stages and 48 hr after coronary ligation. DOB shows good potential for treating acute cardiac insufficiency and cardiogenic shock, as effects on heart rate and blood pressure are weaker.
 ...
PMID:[Comparative study between dobutamine and other catecholamines in their effects on the cardiac contraction and rhythm (author's transl)]. 2 Mar 96

Dobutamine is a newly developed catecholamine reported to have minimal direct vascular effects relative to its inotropic activity and to have less chronotropic and arrhythmogenic properties than other catecholamines used in the treatment of low output states. In this study, the acute hemodynamic effects of dobutamine were compared to those of dopamine in 13 patients with chronic low output cardiac failure. At dosages adjusted to achieve similar increments in cardiac output, dobutamine reduced left ventricular filling pressure (LVEP) from 24 +/- 2 mm Hg (SEM) to 17+/- 2 mm Hg, while dopamine increased LVEP to 30 +/- 3 mm Hg and in six patients caused arterial O2 saturation to fall below 90%. This poor response to dopamine was probably the result of its vasoconstrictive effects and illustrates the potential advantages of using a cardioselective agent such as dobutamine when the desired goal of therapy is to improve ventricular function by direct inotropic stimulation.
 ...
PMID:Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure. 31 33

The haemodynamic effects of dobutamine (2.5 to 10 micrograms/min per kg) were determined in 5 patients without cardiac failure who were undergoing cardiac catheterisation for suspected coronary disease. Myocardial blood flow was determined by the coronary sinus thermodilution technique. Data were compared with those from two groups of 5 patients who received dopamine (4-8 micrograms/min per kg) and isoprenaline (0.005-0.025 micrograms/min per kg). Each drug was given in a lower and a higher dose, and all increased mean cardiac index (dobutamine, 18% and 39%; dopamine, 11% and 23%; isoprenaline, 15% and 44%). These increases were associated with significant increases in mean myocardial oxygen consumption (dobutamine, 38% and 61%; dopamine, 25% and 62%; isoprenaline, 20% and 45%). Mean myocardial blood flow was increased by each drug but mean myocardial oxygen extraction was decreased by isoprenaline, was increased by dopamine, and was unchanged by dobutamine. Each inotropic agent has a similar effect on myocardial oxygen consumption, but isoprenaline has a direct coronary vasodilator action while dopamine has a coronary vasoconstrictor action. Dobutamine has no direct effect upon coronary vascular tone.
 ...
PMID:Haemodynamic effects of dobutamine with special reference to myocardial blood flow. A comparison with dopamine and isoprenaline. 47 33

Septic shock associated with depressed myocardial function generally requires the use of catecholamine. Currently dopamine is often selected. Dobutamine is a newly developed catecholamine which has been shown to be of value in severe cardiomyopathic disease. The aim of this work was to determine the most appropriate drug by comparing haemodynamic responses to dopamine and dobutamine in 19 studies carried out in 11 patients with septic shock and heart failure. Cardiac index increased siliarly with dopamine and dobutamine (33%), as did stroke volume (respectively 26.4 and 25%). Arterial pressure increased by 17% with dopamine whereas it did not significantly change with dobutamine due to reduction in vascular resistance of 19%. Dobutamine decreased filling pressure, either right (14%) of left (28%) whilst they slightly but unsignificantly increased with dopamine. Pulmonary shunting increased more with dopamine (47%) than with dobutamine (16%), but PaO2 remained constant with both. Since septic shock is characterized by lowered arterial pressure and vasodilatation it is concluded that effects of dopamine on capacitance and resistance vessels make this drug more suitable. In addition it selectively increases renal blood flow. Nevertheless dobutamine could be appropriate, in case of very high filling pressures, severe peripheral vasoconstriction, marked pulmonary shunting and in some cases where dopamine becomes ineffective.
 ...
PMID:Comparative haemodynamic effects of dopamine and dobutamine in septic shock. 50 Sep 39

Dobutamine pharmacokinetics was investigated in 7 patients with severe cardiac failure. Dobutamine was administered by a constant intravenous infusion at rates of 2.5, 5.0, 7.5, and 10.0 microgram/kg/min. Steady-state plasma levels increased in proportion to the infusion rate, indicating that there was no saturation of the disposition processes. The average total body clearance was found to be 2.35 +/- 1.01 L/min/m2. After termination of the final infusion, plasma levels of dobutamine were monitored to determine the elimination half-life. The disappearance half-life of dobutamine was calculated to be 2.37 +/- 0.7 min and the distribution volume was 0.202 +/- 0.084 L/kg. The limited data suggest that the volume of distribution of dobutamine was related to the extent of edema.
 ...
PMID:Dobutamine pharmacokinetics in severe heart failure. 69 77

Ten patients in severe cardiac failure were treated with dopamine (4 microgram/kg . min) and dobutamine (7.5 microgram/kg.min). Both drugs brought about a similar increase in stroke volume and cardiac output of about 50% and 60%, respectively, accompanied by a fall in peripheral vascular resistance of about 33%. On dopamine the heart rate increased by 12%, but remained unaltered on dobutamine. There was a significant fall in the preload of both ventricles with dobutamine, while ventricular filling pressure during dopamine infusion was only slightly decreased, unchanged or even increased. The pulmonary (wedge) pressure during dopamine infusion averaged 9 mm Hg higher than during dobutamine (P less than 0.001). There is thus the potential danger with dopamine of aggravating pulmonary congestion. Furthermore, the improvement in cardiac function due to dopamine is at the expense of a higher oxygen demand than with dobutamine. Dobutamine is, therfore, preferable to dopamine in the treatment of advanced myocardial failure.
 ...
PMID:[Dopamine and dobutamine in the treatment of severe cardiac failure (author's transl)]. 71 Mar 19

Dobutamine was infused at a rate of 8 mcg/kg/min in 17 patients with or without congestive heart failure. Cardiac output increased from an average 2.92 to 4.45 1/min/m2(p less than 0.001) with no change in mean aortic pressure (93.4 to 97.8 mmHg) and only a slight increase in heart rate (78 to 87 beats/min). Left ventricular end-diastolic pressure decreased from an average 19 to 13.7 mmHg (p less than 0.01). Peak left ventricular dp/dt was doubled (1147 to 2370 mmHg/sec, p less than 0.001) and Vmax increased from 1.08 to 2.18 circ/sec (p less than 0.001). In 10 patients given equi-inotropic doses (100 per cent increase in peak dp/dt) Isoproterenol produced a greater increase in cardiac output (71 percent) than Dobutamine /51 percent). Isoproterenol caused mean aortic pressure to fall significantly (8 percent) while no change was noted with Dobutamine. Accordingly, peripheral vascular resistances were reduced to a greater extent with Isoproterenol than with Dobutamine (p less than 0.05). Mean pulmonary arterial pressure decreased significantly (25 +/- 5.9 to 22 +/- 5.7 mmHg, p less than 0.05) with Isoproterenol infusion and remained unchanged with Dobutamine infusion. Dobutamine increased both stroke work (57 percent) and minute work (83 percent). With Isoproterenol however, only minute work was significantly increased (90 percent). Dobutamine therefore is a potent inotropic drug, with mild chronotropic and peripheral vascular effect and may be valuable in the management of severe heart failure not associated with hypotension.
 ...
PMID:Comparative haemodynamic effects of dobutamine and isoproterenol in man. 89 74

Dobutamine, a new catecholamine with a positive inotropic action, was given by infusion to 9 patients with cardiac failure in a dosage of 5 and 7.5 mug/kg-min over a period of 15 minutes. An improvement of left ventricular function was proven by an increase of cardiac output by 33%, a reduction of end-diastolic pressure from 21 to 14 mm Hg, an improvement of left ventricular ejection fraction from 29 to 39% and of the mean circumferential fibre contraction velocity from 0.4 to 0.8 circ/s. The systolic aortic pressure increased by a mean of 14% (5 mug/kg-min) and 23% (7.5 mug/kg-min). However, the resistance of the systemic circulation decreased from 1858 to 1439 and 1444 dyn-s-cm-5. Cardiac frequency remained unchanged with a dosage of 5 mug/kg-min and increased by a mere 7 beats/min with a dosage of 7.5 mug/kg-min. There was no increased tendency for arrhythmia. Dobutamine thus appears to act relatively selectively on myocardial beta-1 receptors. Results so far indicate therapeutic success in patients with severe cardiac failure, particularly in the low-output syndrome.
 ...
PMID:[Haemodynamic effect of dobutamine in cardiac failure (author's transl)]. 99 68

Dobutamine (dobutamin hydrochloride, Lilly) is a new inotropic catecholamine; it is presented in lyophilized ampoules for I.V. use, each containing 250 mg of dobutamine to be reconstituted with 5 per cent glucose or sterile water for injection. In the first part of this study, animal pharmacology is reported as described in medical literature: inotropic activity with minimal chronotropic effects, direct action, no vasconstriction, minimal arrhythmogenic activity and minimal diversion of blood flow to skeletal muscles are the main experimental features. The authors report afterwards their own experience with dobutamine in 8 patients (cranial traumas) without cardiac failure, and in 9 patients presenting with a cardio-circulatory failure in a toxi-infectious condition. In all patients tested, hemodynamics parameters (heart rate, mean A.P., central venous pressure) and cardiac output measurement (dye dilution method) were performed. Cardiac index and systolic index, total systemic resistances, left ventricular performance were also calculated. Dobutamine dosage ranged from 2.5 to 10 mcg/kg/mn except in patients with low output syndrom (2.5 and 5 mcg/kg/mn). Dobutamine offers new possibilities by its constant and indisputable inotropic activity contrasting with its minimal chronotropic effect.
 ...
PMID:[A comparative study of the cardiovascular effect of dobutamine. Preliminary results obtained in a surgical resuscitation unit]. 101 59

Dobutamine, a derivative of dopamine, was infused at a rate of 10 mug/kg per min in 15 patients with severe congestive heart failure. Cardiac output increased from an average of 3.1 to 5.6 liters/min (P less than 0.001) with no change in mean arterial pressure (93.3 to 98.2 mm Hg) and only a slight increase in heart rate (98.5 to 105.2 beats/min) (P less than 0.02). Pulmonary wedge pressure was decreased from an average of 27.4 to 21.1 mm Hg (P less than 0.001). In seven patients a dose of 5 mug/kg per min also produced a significant increase in cardiac output but the effect was less than with the 10 mug/kg per min dose. No side effects were observed during the infusion. Dobutamine therefore is a potent inotropic drug with limited chronotropic and peripheral vascular effects and deserves therapeutic trial in the short-term management of low output heart failure.
 ...
PMID:Hemodynamic effect of dobutamine in patients with severe heart failure. 115 41


1 2 3 4 5 6 7 8 9 10 Next >>